SCHOTT Pharma : Financial Factsheet Q1 2026

About this update from Schott Pharma Ag & Co. Kgaa

Financial factsheet Q1 2026 October 1, 2025 - December 31, 2025 SCHOTT Pharma Results of operations (in EUR m / in %) Q1 2026 Q1 2025 Revenue 240.2 231.4 Revenue growth at constant currencies +4.8% +4.8% High-value solutions (HVS) revenue share 57% 55% EBITDA 65.2 58.7 EBITDA margin 27.1% 25.4% EBIT 43.8 40.2 EBIT margin 18.2% 17.4% Financial result -1.8 -3.4 Income tax expenses -8.8 -7.0 Profit for the period 33.3 29.8 Earnings per share (in EUR) 0.22 0.20 Financial position (in EUR m) Q1 2026 Q1 2025 Cash flows from operating activities 3.4 25.1 Cash flows from ongoing investing activities -23.2 -21.0 Free cash flow -19.8 4.1 Net assets (in EUR m / in %) Dec. 31, 2025 Sep. 30, 2025 Working capital 244.1 199.3 Working capital in % of revenue 25.4% 20.2% Equity ratio 57.3% 55.9% Net debt 146.9 122.2 Employees Dec. 31, 2025 Sep. 30, 2025 Revenue bridge (in EUR m) +4.8% -1.0% +3.8% -2.4 240.2 231.4 +11.2 Q1 2025 Organic growth FX Q1 2026 Revenue by region (in EUR m) HVS revenue share Q1 2026 (in %) 22.2 43.2 37.8 Q1 2026 137.0 43% 57% EMEA APAC 137.2 EBITDA margin EBIT EBIT margin 24.3% 24.1 17.6% 21.9% 19.0 14.8% Q1 2025 Organic growth FX Q1 2026 Drug Delivery Systems (DDS) Revenue bridge (in EUR m) +12.1 128.3 (in EUR m) -3.2 103.1 -0.9 +0.8 103.1 EBIT margin 20.0% 25.1% Q1 2025 Organic growth FX Q1 2026 North America South America HVS Core Headcount (as of the reporting date) 4,829 4,811 Drug Containment Solutions (DCS) Revenue bridge Results of operations (in EUR m / in %) Q1 2026 Q1 2025 +9.4% -2.5% +6.9% Revenue 137.2 128.3 EBITDA 33.4 28.1 Results of operations (in EUR m / in %) Q1 2026 Q1 2025 -0.8% +0.8% -0.0% Revenue 103.1 103.1 EBITDA 32.6 35.1 EBITDA margin 31.6% 34.1% EBIT 20.7 25.9

View stock analysis, news, and events for Schott Pharma Ag & Co. Kgaa